FDA approval and first generic launch of Acticlate tablets
Filed with ASX · · 1 page · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
15 Jun 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of its Abbreviated New Drug Application (ANDA) for doxycycline hyclate immediate release (IR) tablets (75 mg and 150 mg) in the United States. Mayne Pharma has immediately commenced commercial launch to customers in the US. Doxycycline hy
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Clarification statement
- Mayne Pharma acquires rights to generic Duragesic in the US
- License and supply agreement for generic Nuvaring in the US
- 2017 Half Year Media Release
- Mayne Pharma launches Butalbital / APAP tablets in the US
Later from Mayne Pharma
- Mayne Pharma adds two products to its Australian portfolio
- Mayne Pharma launches clozapine tablets in the US
- 2017 CEOs Speech
- 2018 Half Year Media Release
- 2018 Half Year Investor Presentation
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma